巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Relmada Therapeutics

    RLMD
    37.070
    0.920
    2.54%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Relmada Therapeutics - 延遲價格・最後更新於 30/09 8:33
    最高位
    38.500
    最低位
    35.680
    開市價
    --
    前收市價
    36.150
    成交量(千)
    47.30
    成交額(百萬)
    15.29
    買入
    30.140
    賣出
    46.120
    每手股數
    --
    市值(百萬)
    1,060.52
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    38.680 - 15.735
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Relmada Therapeutics
    證券代碼
    RLMD.US
    所屬板塊
    Biotechnology
    公司業務
    Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
    發行量
    29369490
    公司總部
    2222 Ponce de Leon Boulevard, Floor 3
    公司網址
    https://www.relmada.com
    公司電郵
    straversa@relmada.com
    公司電話
    +1 786 629-1376
    暫無內容

    關於

    Relmada Therapeutics(RLMD.US)所屬的行業板塊為Biotechnology。
    Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
    詳細公司背景可參考: https://www.relmada.com